Silver Book Fact

A large set of NIH clinical trials are assessing interventions (including dietary supplements–creatine and coenzyme Q10) that may slow the progression of Parkinson’s disease.

Ravina B, Fagan S, Hart R, Hovinga C, et al. Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment. Neurology. 2003; 60(8): 1234-40. http://www.neurology.org/cgi/pmidlookup?view=long&pmid=12707423

Reference

Title
Neuroprotective Agents for Clinical Trials in Parkinson’s Disease: A systematic assessment
Publication
Neurology
Publication Date
2003
Authors
Ravina B, Fagan S, Hart R, Hovinga C, et al
Volume & Issue
Volume 60, Issue 8
Pages
1234-40
URL
Read Full Resource

Categories

  • Innovative Medical Research
  • Future Value

Related Facts

  • “If you or a loved one started exhibiting symptoms of Alzheimer’s disease 12 years ago, there were no medicines for you to take. All you could do was hope–that…  
  • According to the Pharmaceutical Research and Manufacturers of America, 42 medicines are currently in development for Alzheimer’s disease.  
  • A treatment that delayed the age of onset of Alzheimer’s disease by five years would reduce the proportion of Americans age 65 and older with the disease from 10% to…  
  • A medicine is in development that aims to prevent or reverse Alzheimer’s disease progression by using a human monoclonal antibody specifically designed to remove beta amyloid protein from the brain.  
  • According to the Pharmaceutical Research and Manufacturers of America, 21 new medicines are currently in development for the treatment of Parkinson’s disease.